These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 20306038

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
    Evangelista L, Cuppari L, Guttilla A, Gardi M, Agostini A, Ruggera L, Basso U, Saladini G.
    Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
    [Abstract] [Full Text] [Related]

  • 23. [(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy.
    Rinnab L, Simon J, Hautmann RE, Cronauer MV, Hohl K, Buck AK, Reske SN, Mottaghy FM.
    World J Urol; 2009 Oct; 27(5):619-25. PubMed ID: 19234708
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H.
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [Abstract] [Full Text] [Related]

  • 27. Correlation of [11C]choline PET-CT with time to treatment and disease-specific survival in men with recurrent prostate cancer after radical prostatectomy.
    Breeuwsma AJ, Rybalov M, Leliveld AM, Pruim J, de Jong IJ.
    Q J Nucl Med Mol Imaging; 2012 Oct; 56(5):440-6. PubMed ID: 23069923
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. 68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.
    Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, Fanti S.
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):31-39. PubMed ID: 30350010
    [Abstract] [Full Text] [Related]

  • 31. Diagnostic performance of F-18 fluciclovine PET/CT in post-radical prostatectomy prostate cancer patients with rising prostate-specific antigen level ≤0.5 ng/mL.
    Teyateeti A, Khan B, Teyateeti A, Chen B, Bridhikitti J, Pan T, Peng W, Macapinlac HA, Lu Y.
    Nucl Med Commun; 2020 Sep; 41(9):906-915. PubMed ID: 32796479
    [Abstract] [Full Text] [Related]

  • 32. A pilot study of the utility of choline PET-CT in prostate cancer biochemical relapse following radical prostatectomy.
    Tan H, Joseph D, Loh NK, McCarthy M, Leong E, Siew T, Segard T, Morandeau L, Trevenen M, Francis RJ.
    J Med Imaging Radiat Oncol; 2016 Jun; 60(3):374-81. PubMed ID: 27094471
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. First imaging results of an intraindividual comparison of (11)C-acetate and (18)F-fluorocholine PET/CT in patients with prostate cancer at early biochemical first or second relapse after prostatectomy or radiotherapy.
    Buchegger F, Garibotto V, Zilli T, Allainmat L, Jorcano S, Vees H, Rager O, Steiner C, Zaidi H, Seimbille Y, Ratib O, Miralbell R.
    Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):68-78. PubMed ID: 24104592
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Evaluation of tumor recurrences after radical prostatectomy using 18F-Choline PET/CT and 3T multiparametric MRI without endorectal coil: a single center experience.
    Couñago F, Recio M, Maldonado A, Del Cerro E, Díaz-Gavela AA, Thuissard IJ, Sanz-Rosa D, Marcos FJ, Olaciregui K, Mateo M, Cerezo L.
    Cancer Imaging; 2016 Dec 07; 16(1):42. PubMed ID: 27927229
    [Abstract] [Full Text] [Related]

  • 37. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
    Brockman JA, Alanee S, Vickers AJ, Scardino PT, Wood DP, Kibel AS, Lin DW, Bianco FJ, Rabah DM, Klein EA, Ciezki JP, Gao T, Kattan MW, Stephenson AJ.
    Eur Urol; 2015 Jun 07; 67(6):1160-1167. PubMed ID: 25301759
    [Abstract] [Full Text] [Related]

  • 38. Prostate-Specific Antigen and Prostate-Specific Antigen Kinetics in Predicting 18F-Sodium Fluoride Positron Emission Tomography-Computed Tomography Positivity for First Bone Metastases in Patients with Biochemical Recurrence after Radical Prostatectomy.
    Yoon J, Ballas L, Desai B, Jadvar H.
    World J Nucl Med; 2017 Jun 07; 16(3):229-236. PubMed ID: 28670183
    [Abstract] [Full Text] [Related]

  • 39. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
    Verburg FA, Pfister D, Heidenreich A, Vogg A, Drude NI, Vöö S, Mottaghy FM, Behrendt FF.
    Eur J Nucl Med Mol Imaging; 2016 Mar 07; 43(3):397-403. PubMed ID: 26563121
    [Abstract] [Full Text] [Related]

  • 40. Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial.
    Ceci F, Herrmann K, Castellucci P, Graziani T, Bluemel C, Schiavina R, Vollmer C, Droll S, Brunocilla E, Mazzarotto R, Buck AK, Fanti S.
    Eur J Nucl Med Mol Imaging; 2014 Dec 07; 41(12):2222-31. PubMed ID: 25182750
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.